胸膜痛の治療市場：診断、治療、投与方法、エンドユーザー別-2025～2030年の世界予測

胸膜痛の治療市場は、2023年に1億3,843万米ドルと評価され、2024年には1億4,540万米ドルに達すると予測され、CAGR 5.66％で成長し、2030年には2億354万米ドルに達すると予測されています。

ボーンホルム病として一般的に知られる胸膜炎は、下胸部と上腹部の激しい筋肉痛を引き起こす急性のウイルス感染症です。多くの場合、コクサッキーBウイルスによって引き起こされ、その治療は、決定的な治療というよりは、症状の管理に主眼が置かれています。胸膜痛の治療の必要性は、急性でしばしば衰弱させる症状から生じ、患者の運動能力や生活の質を著しく制限します。治療は主に緩和的なもので、鎮痛薬や抗炎症薬を用いて痛みを和らげたり炎症を抑えたりします。最終用途には、一次治療や支持療法が行われる病院、クリニック、外来が含まれます。

市場の成長は、ウイルス感染症の流行と効果的な疼痛管理ソリューションに対する需要の高まりに影響されています。主要成長要因としては、抗ウイルス療法の進歩、ウイルス感染の影響に対する認識、より良い管理方法に貢献する迅速診断法の開発などが挙げられます。より効果的な抗ウイルス薬や、ウイルスの根本的な原因を対象にした治療法の開発、即効性のある疼痛緩和ソリューションの革新などが機会となります。企業にとっては、市販の疼痛管理ソリューションへの多角化や、包括的なケアパッケージのための医療プロバイダーとの提携が重要な機会となります。

しかし、胸膜炎の疫学の理解が限られていることや、既存の治療法の潜在的な副作用などの課題が、成長の制約となっています。特定の治療が限られており、対症療法に依存していることから、新規治療研究の必要性が指摘されています。規制上のハードルや新薬の厳しい承認プロセスも、市場の勢いを削ぐ可能性があります。

技術革新が期待されるセグメントとしては、標的を絞った抗ウイルス療法の開発や、疼痛管理ソリューションを強化し、治療をより安全かつ効率的にするためのバイオテクノロジーの活用の模索などが挙げられます。この市場は患者中心の市場であり、症状の緩和を重視する傾向があるため、胸膜透析を迅速に特定する診断ツールの強化は、患者の予後を大幅に改善し、市場拡大を促進する可能性があります。この市場の性質は高度に専門化されているため、持続的な成長を促進し、治療格差に対処するためには、製薬企業と医療機関の間に強固なパートナーシップを構築することが重要です。

市場力学：急速に進化する胸膜痛の治療市場の主要市場洞察を公開

胸膜痛の治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネス機会の獲得に備えることができます。こうした動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • ウイルス感染症と胸膜炎の有病率の増加
  • 新薬導入のための研究開発活動の活発化
• 市場抑制要因
  • 研究開発コストの上昇
• 市場機会
  • 医療の成果における技術の進歩と近代化
• 市場課題
  • 厳しい規制ガイドライン

ポーターのファイブフォース：胸膜痛の治療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォースフレームワークは、企業の競合を評価し、戦略的機会を探るための明確な手法を記載しています。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これら洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：胸膜痛の治療市場における外部からの影響の把握

外部マクロ環境要因は、胸膜痛の治療市場の業績力学を形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を記載しています。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析：胸膜痛の治療市場における競合情勢の把握

胸膜痛の治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、セグメント化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニングマトリックス：胸膜痛の治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、胸膜痛の治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨：胸膜痛の治療市場における成功への道筋を描く

胸膜痛の治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネス機会を活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目セグメントを網羅した市場の包括的な分析を提供しています。

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力を評価します。

2.市場の開拓度：新興市場における成長機会を特定し、既存セグメントにおける拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを記載しています。

3.市場の多様化：最近の製品発売、未開拓の地域、産業の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発とイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています。

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、地域はどこか？

3.市場を形成する主要技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • ウイルス感染症の蔓延と胸膜炎の蔓延の増加
    • 新薬導入に向けた研究開発活動の活発化
  • 抑制要因
    • 研究開発活動のコストの上昇
  • 機会
    • 医療成果における技術の進歩と近代化
  • 課題
    • 厳格な規制ガイドライン
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治
  • 経済
  • 社会
  • 技術
  • 法律
  • 環境

第6章 胸膜痛の治療市場：診断別

• イントロダクション
• 血液検査
• 培養検査
• X線

第7章 胸膜痛の治療市場：治療別

• イントロダクション
• 鎮痛剤
• 免疫グロブリン

第8章 胸膜痛の治療市場：投与方法別

• イントロダクション
• 注射
• 経口

第9章 胸膜痛の治療市場：エンドユーザー別

• イントロダクション
• 病院
• 薬局

第10章 南北アメリカの胸膜痛の治療市場

• イントロダクション
• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋の胸膜痛の治療市場

• イントロダクション
• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの胸膜痛の治療市場

• イントロダクション
• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析、2023年
• FPNVポジショニングマトリックス、2023年
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Alkem Laboratories Limited
• Cipla Limited
• Dr. Reddy's Laboratories
• GlaxoSmithKline PLC
• Glenmark Pharmaceuticals Limited
• Hetero Drugs
• Johnson & Johnson Services, Inc.
• Lupin Limited
• Merck and Co. Inc.
• Novartis AG
• Opsonin Pharma Ltd.
• Pfizer Inc.
• Reckitt Benckiser Group PLC
• Sanofi S.A.

LIST OF FIGURES

• FIGURE 1. PLEURODYNIA TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. PLEURODYNIA TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. PLEURODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. PLEURODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. PLEURODYNIA TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. PLEURODYNIA TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY CULTURE TEST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY X-RAY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY IMMUNOGLOBULIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL PLEURODYNIA TREATMENT MARKET SIZE, BY PHARMACY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 27. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 30. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 33. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 34. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 35. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 36. CANADA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES PLEURODYNIA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 55. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 56. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 57. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 58. CHINA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 60. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 61. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 62. INDIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 64. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 65. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 66. INDONESIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 67. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 68. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 69. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 70. JAPAN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 72. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 73. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 74. MALAYSIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 76. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 77. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 78. PHILIPPINES PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 79. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 80. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 81. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 82. SINGAPORE PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 84. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 85. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 86. SOUTH KOREA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 88. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 89. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 90. TAIWAN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 92. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 94. THAILAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 95. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 96. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 97. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 98. VIETNAM PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 99. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 100. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 101. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 102. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. EUROPE, MIDDLE EAST & AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 104. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 105. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 106. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 107. DENMARK PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 109. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 111. EGYPT PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 113. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 114. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 115. FINLAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 116. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 117. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 118. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 119. FRANCE PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 120. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 121. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 122. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 123. GERMANY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 125. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 126. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 127. ISRAEL PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 129. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 130. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 131. ITALY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 132. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 133. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 135. NETHERLANDS PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 137. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 138. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 139. NIGERIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 140. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 141. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 142. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 143. NORWAY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 145. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 146. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 147. POLAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 149. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 150. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 151. QATAR PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 153. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 154. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 155. RUSSIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 156. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 157. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 158. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 159. SAUDI ARABIA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 160. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 161. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 162. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH AFRICA PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 165. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 166. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 167. SPAIN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 168. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 169. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 170. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 171. SWEDEN PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 172. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 173. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 174. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 175. SWITZERLAND PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 177. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 178. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 179. TURKEY PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 181. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 182. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 183. UNITED ARAB EMIRATES PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
• TABLE 185. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 186. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2030 (USD MILLION)
• TABLE 187. UNITED KINGDOM PLEURODYNIA TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. PLEURODYNIA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 189. PLEURODYNIA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

The Pleurodynia Treatment Market was valued at USD 138.43 million in 2023, expected to reach USD 145.40 million in 2024, and is projected to grow at a CAGR of 5.66%, to USD 203.54 million by 2030.

Pleurodynia, commonly known as Bornholm disease, is an acute viral infection leading to severe muscle pain in the lower chest and upper abdomen. Often caused by Coxsackie B viruses, its treatment primarily focuses on symptom management rather than a definitive cure. The necessity of pleurodynia treatment arises from its acute, often debilitating symptoms, which can severely restrict patient mobility and quality of life. Applications of treatment are mainly palliative, involving analgesics and anti-inflammatory medications, to alleviate pain and reduce inflammation. The end-use scope includes hospitals, clinics, and outpatient settings where primary and supportive care are administered.

Market growth is influenced by the prevalence of viral infections and the increasing demand for effective pain management solutions. Key growth factors include advancements in antiviral therapies, awareness of viral infection ramifications, and the development of rapid diagnostics contributing to better management practices. Opportunities arise in creating more effective antiviral drugs or therapies targeting the root viral causes, along with innovations in fast-acting pain relief solutions. For businesses, diversification into over-the-counter pain management solutions and partnerships with healthcare providers for comprehensive care packages present key opportunities.

However, challenges such as limited understanding of the epidemiology of pleurodynia, coupled with potential side effects of existing treatments, pose growth constraints. Limited specific drug treatments and reliance on symptomatic relief indicate the need for novel therapeutic research. Regulatory hurdles and stringent approval processes for new drug entities may also dampen market momentum.

Promising areas for innovation include developing targeted antiviral therapies and exploring the use of biotechnology to enhance pain management solutions, making treatments safer and more efficient. As the market is patient-centric with an inclination towards symptomatic relief, enhanced diagnostic tools to rapidly identify pleurodynia can significantly elevate patient outcomes and drive market expansion. The nature of this market is highly specialized, emphasizing the creation of robust partnerships between pharmaceutical entities and healthcare institutions to drive sustained growth and address treatment gaps.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pleurodynia Treatment Market

The Pleurodynia Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing prevalence of viral infections and increasing prevalence of pleurodynia disease
  • Rising R&D activities for introducing new medications
• Market Restraints
  • Rise in the cost of research and development activities
• Market Opportunities
  • Technological advancements and modernization in the healthcare outcomes
• Market Challenges
  • Stringent regulatory guidelines

Porter's Five Forces: A Strategic Tool for Navigating the Pleurodynia Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pleurodynia Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pleurodynia Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pleurodynia Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pleurodynia Treatment Market

A detailed market share analysis in the Pleurodynia Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pleurodynia Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pleurodynia Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pleurodynia Treatment Market

A strategic analysis of the Pleurodynia Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pleurodynia Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Alkem Laboratories Limited, Cipla Limited, Dr. Reddy's Laboratories, GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Hetero Drugs, Johnson & Johnson Services, Inc., Lupin Limited, Merck and Co. Inc., Novartis AG, Opsonin Pharma Ltd., Pfizer Inc., Reckitt Benckiser Group PLC, and Sanofi S.A..

Market Segmentation & Coverage

This research report categorizes the Pleurodynia Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Diagnosis, market is studied across Blood Test, Culture Test, and X-ray.
• Based on Treatment, market is studied across Analgesics and Immunoglobulin.
• Based on Mode Of Administration, market is studied across Injections and Oral.
• Based on End-User, market is studied across Hospitals and Pharmacy.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing prevalence of viral infections and increasing prevalence of pleurodynia disease
    • 5.1.1.2. Rising R&D activities for introducing new medications
  • 5.1.2. Restraints
    • 5.1.2.1. Rise in the cost of research and development activities
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements and modernization in the healthcare outcomes
  • 5.1.4. Challenges
    • 5.1.4.1. Stringent regulatory guidelines
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Pleurodynia Treatment Market, by Diagnosis

• 6.1. Introduction
• 6.2. Blood Test
• 6.3. Culture Test
• 6.4. X-ray

7. Pleurodynia Treatment Market, by Treatment

• 7.1. Introduction
• 7.2. Analgesics
• 7.3. Immunoglobulin

8. Pleurodynia Treatment Market, by Mode Of Administration

• 8.1. Introduction
• 8.2. Injections
• 8.3. Oral

9. Pleurodynia Treatment Market, by End-User

• 9.1. Introduction
• 9.2. Hospitals
• 9.3. Pharmacy

10. Americas Pleurodynia Treatment Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Pleurodynia Treatment Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Pleurodynia Treatment Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
• 13.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Alkem Laboratories Limited
• 3. Cipla Limited
• 4. Dr. Reddy's Laboratories
• 5. GlaxoSmithKline PLC
• 6. Glenmark Pharmaceuticals Limited
• 7. Hetero Drugs
• 8. Johnson & Johnson Services, Inc.
• 9. Lupin Limited
• 10. Merck and Co. Inc.
• 11. Novartis AG
• 12. Opsonin Pharma Ltd.
• 13. Pfizer Inc.
• 14. Reckitt Benckiser Group PLC
• 15. Sanofi S.A.